Researchers from UC Davis Comprehensive Cancer Center is testing a drug called niraparib (Zejula), given before prostate cancer surgery. Researchers think it could enable more personalized treatments—especially for men with prostate cancer that has specific DNA repair gene mutations.
As complementary and alternative medicines continue to gain acceptance beyond the margins of cancer treatment, results from a recent study from Yale School of Medicine published in JAMA Network Open suggests that some patients using CAM with their mainstream therapy may, in fact, be substituting alternative medicine for allopathinc interventions.
